Page 27 - Adverse Effects News Today : Breaking News, Live Updates & Top Stories | Vimarsana

'The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway.'

Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs, but the effect was not found at 24 weeks.

"We are seeing some truly surprising response rates and progression-free survival data," says chairman of Unicancer and general director of the Léon Bérard Center in France.

A model showed that pharmacogenomic testing of patients with newly diagnosed major depressive disorder could save the health system $956 million CAD over 20 years.

A systematic review and meta-analysis support the use of oral naltrexone and acamprosate, coupled with psychosocial support, to reduce drinking among adults with alcohol use disorder.